ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. The primary goal of the planned Phase 2 trial will be to establish efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor in first-recurrenc ...

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. GeoVax and a specially convened clinical advisory committ ...

Compelling Relevance Is Moving GOVX Stock Although Covid-19 fears have been fading since late 2021 and early 2022, the virus remains a major concern. According to the Centers for Disease Control and Prevention (CDC), addressing Covid "remains a public health priority." According to a press release, the company previously disclosed that it was a recipient of an award via the Rapid Response Partnership Vehicle (RRPV) for the development of its GEO-CM04S1 Covid vaccine. The Biomedical Advanced Research and Dev ...

Exhibit 99.1 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad ef icacy of the vaccine candidate Significant milestone achieved towards implementation of a commercially validated manufacturing system Progress across pipeline with planned data readouts for GEO-CM04S1 in multiple trials and Gedeptin® in healthy patient boost trial on track f ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Robert LeBoyer - Noble Capital Markets Operator Good afternoon, and welcome everyone to the GeoVax First Quarter 2024 Corporate Update Call. My name is Ma ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Drive, Suite 38 ...

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC. During his presentat ...

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024. Presentation Details: Presenter:       David Dodd, Chairman & CEODate/Time:      March 18, 2024, 2:30 pm PTLocation:         Dana Point, CAWebcast Li ...

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company's MVA-based vaccines, with the release of its fi ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Max Gadicke - Stern, IR David Dodd - Chairman and CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer John Sharkey - VP, Business Development Conference Call Participants Laura Suriel - Alliance Global Partners Jeffrey Kraws - Crystal Research Robert LeBoyer - NOBLE Capital Markets Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Operator Good afternoon, and welcome, eve ...